Follow DNDi on LinkedInFollow DNDi on TwitterFollow DNDi on Facebook

Over 1 billion people, including 500 million children, in the poorest regions of the world, are affected by neglected diseases that debilitate, disfigure or kill.

DNDi’s research and development approach is driven by the real day-to-day needs of patients and healthcare providers.

By connecting public and private partners, DNDi synergizes expertise and capitalizes upon the best science. 

DNDi also works to strengthen the health R&D field in the countries where the diseases occur in order to reinforce capacities for sustainable change.

Major progress has been made with six new treatments made available since the creation of DNDi, in 2003. However, major breakthroughs are still needed to treat neglected patients: Entirely new, affordable, and adapted drugs will change the lives of millions of people.


DNDi 2014 Annual Report

Read DNDi's 2014 Annual Report: "Partnerships to Bridge Innovation and Access" More

Finding a Cure for Kala Azar

AlJazeera's The Cure travels travels to Japan, Switzerland and Ethiopia to explore how big pharmaceutical companies are being mobilised by DNDi in a new global initiative to find and fast-track a cure for kala-azar. More

Close-up on Chagas Disease

For Juan Bautista Corzo Veloza, a 53 year old, father of three, life is not the same since that day in January 2013 when a stroke left him "dead for three days," he says. More

DNDi and MSF Access Campaign Directors answer questions on Reddit AMA

Bernard Pécoul and Manica Balasegaram answered questions on global health R&D funding on a PLOS Reddit Science AMA. More

DNDi hands over malaria programme to MMV

MMV and DNDi have agreed that the ASAQ and ASMQ products developed by DNDi and its partners will now be managed by the MMV Access and Product Management team. More



September 6-10, 2015
9th European Congress on Tropical Medicine and International Health
Basel, Switzerland
DNDi will be presenting in symposia and poster sessions on visceral leishmaniasis, open source drug discovery, Chagas disease, helminth infections, sleeping sickness, and mycetoma.

October 25 - 29, 2015
ASTMH 2015
Philadelphia, United States
American Society of Tropical Medicine and Hygiene (ASTMH), 64th Annual Meeting. DNDi Medical Director, Nathalie Strub Wourgaft, will be speaking in a session on clinical experience in treating neglected infectious tropical diseases.

See all events



DNDi Model Paper
DNDi has issued a report that explores the lessons learned from a decade of R&D of new treatments for neglected diseases via a cost-effective, innovative, not-for-profit drug development model. Read more


Except for images, films and trademarks which are subject to DNDi’s Terms of Use, content on this site
is licensed under a Creative Commons Attribution-NonCommercial-Share Alike 3.0 Switzerland License